Results of a phase I/II clinical trial by Ambrx Inc. showing that ARX201, the company's long-acting human growth hormone (hGH) analogue, normalised insulin-like growth factor I (IGF-I) levels, were presented at the International Congress of Endocrinology Conference in Rio de Janeiro.

Full article